menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Abreast of the Development of Vaccines to Prevent COVID-19: What Clinicians Need to Know

close
0.75 credits
45 minutes
Keeping Abreast of the Development of Vaccines to Prevent COVID-19: What Clinicians Need to Know
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.

  • Provider Statement

    Provided by Integrity Continuing Education, Inc.

  • Supporter Acknowledgement

    Supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

  • Disclosure of Conflicts of Interest

    The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

    Angela Rasmussen, PhD
    Consulting Fees: Edelman, Guidepoint, Health Advances, Healthineers, IMS Expert Services, Principal, Select Equity, Siemens, W2O
    Speakers Bureaus: HHMI Janelia, Johns Hopkins, MJH Life Sciences, Smith College
    Ownership Interest: Illumina, Nanostring, Pacific Biosciences, TheroFisher

    Carlos del Rio, MD
    Consulting Fees: Sanofi Pasteur

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed to meet the needs of infectious disease experts, immunologists, geriatricians, primary care physicians, nurse practitioners, physician’s assistants, nurses, and other members of the health care team involved in, or interested in, education regarding COVID-19 vaccines.

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

  • Disclaimer

    Disclosure of Unlabled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.

  • Provider Statement

    Provided by Integrity Continuing Education, Inc.

  • Supporter Acknowledgement

    Supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

  • Disclosure of Conflicts of Interest

    The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

    Angela Rasmussen, PhD
    Consulting Fees: Edelman, Guidepoint, Health Advances, Healthineers, IMS Expert Services, Principal, Select Equity, Siemens, W2O
    Speakers Bureaus: HHMI Janelia, Johns Hopkins, MJH Life Sciences, Smith College
    Ownership Interest: Illumina, Nanostring, Pacific Biosciences, TheroFisher

    Carlos del Rio, MD
    Consulting Fees: Sanofi Pasteur

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed to meet the needs of infectious disease experts, immunologists, geriatricians, primary care physicians, nurse practitioners, physician’s assistants, nurses, and other members of the health care team involved in, or interested in, education regarding COVID-19 vaccines.

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

  • Disclaimer

    Disclosure of Unlabled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/30/21